Chalkia Aglaia, Petras Dimitrios
Nephrology Department, Hippokration General Hospital, Athens, Greece.
Nephrology Department, Hippokration General Hospital, Athens, Greece.
Transfus Apher Sci. 2024 Feb;63(1):103847. doi: 10.1016/j.transci.2023.103847. Epub 2023 Nov 17.
ANCA-associated Vasculitides (AAV) are characterized by small vessel necrotizing inflammation and can present with multisystem organ involvement, including organ/life threatening manifestations of rapidly progressive glomerulonephritis and diffuse alveolar haemorrhage, where immediate and aggressive intervention is needed to prevent further organ damage. Although, the rationale of plasma exchange (PLEX) in AAV is strong, through removing the pathogenic ANCAs; target either myeloperoxidase (MPO) or proteinase 3 (PR3), and other inflammatory molecules, especially in the initiation when the immunosuppressive treatment is no sufficient to prevent the organ damage, overall impact on patient outcomes is not well-established, while the risk of infections seems to be higher in the PLEX-treated patients. A comprehensive overview of the challenges and uncertainties surrounding the use of PLEX in the management of AAV will be reviewed, providing the current practice recommendations guiding treatment decisions.
抗中性粒细胞胞浆抗体相关血管炎(AAV)的特征是小血管坏死性炎症,可表现为多系统器官受累,包括快速进展性肾小球肾炎和弥漫性肺泡出血等危及器官/生命的表现,对此需要立即进行积极干预以防止进一步的器官损害。尽管血浆置换(PLEX)在AAV治疗中的理论依据充分,通过清除致病性抗中性粒细胞胞浆抗体(ANCA);其靶点为髓过氧化物酶(MPO)或蛋白酶3(PR3),以及其他炎症分子,尤其是在免疫抑制治疗不足以防止器官损害的起始阶段,但对患者预后的总体影响尚未明确,而接受PLEX治疗的患者感染风险似乎更高。本文将综述在AAV管理中使用PLEX所面临的挑战和不确定性的全面概述,提供指导治疗决策的当前实践建议。